Vanguard Personalized Indexing Management LLC Buys Shares of 7,429 BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Vanguard Personalized Indexing Management LLC bought a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIOFree Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 7,429 shares of the company’s stock, valued at approximately $300,000.

Other hedge funds have also modified their holdings of the company. Arizona State Retirement System grew its stake in BridgeBio Pharma by 1.6% during the 3rd quarter. Arizona State Retirement System now owns 25,134 shares of the company’s stock worth $663,000 after buying an additional 386 shares during the last quarter. Diversified Trust Co raised its position in shares of BridgeBio Pharma by 2.5% in the 3rd quarter. Diversified Trust Co now owns 17,111 shares of the company’s stock valued at $451,000 after purchasing an additional 411 shares during the last quarter. Amalgamated Bank boosted its stake in BridgeBio Pharma by 3.8% in the 3rd quarter. Amalgamated Bank now owns 15,775 shares of the company’s stock worth $416,000 after purchasing an additional 576 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its position in BridgeBio Pharma by 4.9% during the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 15,289 shares of the company’s stock worth $403,000 after purchasing an additional 720 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in BridgeBio Pharma by 1.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 65,773 shares of the company’s stock valued at $2,655,000 after purchasing an additional 904 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Stock Performance

Shares of NASDAQ BBIO opened at $27.94 on Tuesday. BridgeBio Pharma, Inc. has a 1 year low of $12.75 and a 1 year high of $44.32. The company’s fifty day moving average price is $27.94 and its 200 day moving average price is $32.11. The company has a market capitalization of $5.23 billion, a PE ratio of -8.68 and a beta of 1.08.

BridgeBio Pharma (NASDAQ:BBIOGet Free Report) last posted its earnings results on Thursday, May 2nd. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.35. The business had revenue of $211.12 million for the quarter, compared to analyst estimates of $140.06 million. On average, equities analysts expect that BridgeBio Pharma, Inc. will post -3.2 EPS for the current year.

Wall Street Analyst Weigh In

BBIO has been the topic of a number of research analyst reports. Cantor Fitzgerald boosted their price objective on shares of BridgeBio Pharma from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th. HC Wainwright reduced their price objective on BridgeBio Pharma from $47.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, May 20th. Mizuho dropped their target price on BridgeBio Pharma from $60.00 to $53.00 and set a “buy” rating on the stock in a research report on Tuesday, March 5th. Citigroup raised their price target on shares of BridgeBio Pharma from $42.00 to $46.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. Finally, Evercore ISI assumed coverage on shares of BridgeBio Pharma in a report on Tuesday, May 14th. They issued an “outperform” rating and a $50.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $47.67.

Read Our Latest Stock Analysis on BridgeBio Pharma

Insider Buying and Selling at BridgeBio Pharma

In other news, Director Randal W. Scott sold 2,500 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $34.00, for a total transaction of $85,000.00. Following the completion of the sale, the director now owns 6,500 shares of the company’s stock, valued at $221,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 24.66% of the stock is owned by corporate insiders.

BridgeBio Pharma Profile

(Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

See Also

Institutional Ownership by Quarter for BridgeBio Pharma (NASDAQ:BBIO)

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.